Aduro Biotech, Inc. is a global immuno-oncology company that is developing new combination treatments based on three broad, proprietary immunotherapy platforms. These approaches modulate the tumor-immune system interface in multiple, complementary ways to potentially increase the efficacy of immunotherapy for
Aduro’s novel immunotherapies are designed to induce highly targeted, potent and sustained immune responses against a variety of cancers.
Aduro Biotech is headquartered in Berkeley, California. Aduro Biotech Europe is a subsidiary based in Oss, Netherlands.